This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lu, Y. Articles by Fan, Z. Search for Related Content PubMed PubMed Citation Articles by Lu, Y. Articles by Fan, Z.

Epidermal Growth Factor Receptor (EGFR) Ubiquitination as a Mechanism of Acquired Resistance Escaping Treatment by the Anti-EGFR Monoclonal Antibody Cetuximab

Departments of ¹ Experimental Therapeutics and ² Systems Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Zhen Fan, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 036, Houston, TX 77030. Phone: 713-745-3560; Fax: 713-745-3562; E-mail: zfan{at}mdanderson.org.

Cetuximab is an epidermal growth factor receptor (EGFR)–blocking antibody that has been approved for treatment of patients with metastatic colorectal cancer. In this study, we investigated biochemical changes in signaling pathways of a cetuximab-resistant subline of DiFi colorectal cancer cells (DiFi5) that was developed by exposing the parental sensitive cells to subeffective doses of cetuximab over an extended period of time. Compared with parental DiFi cells that express high levels of EGFR and in which cetuximab induces apoptosis, the cetuximab-resistant DiFi5 cells showed markedly lower protein levels of EGFR, an increased association of EGFR with Cbl, and an increased ubiquitination of EGFR. DiFi5 cells also had a markedly higher level of Src-Y416 phosphorylation both at baseline and on EGF stimulation. Although EGFR levels were low, DiFi5 cells responded to EGF stimulation with robust phosphorylation of EGFR on Y845 and strong phosphorylation of Akt and extracellular signal–regulated kinase, comparable to those of parental cells. Most importantly, inhibition of Src kinase activity with PP2 reversed the resistance of DiFi5 cells to cetuximab-induced apoptosis without affecting the levels of EGFR in the cells. Our results indicate that colorectal cancer cells may develop acquired resistance to cetuximab via altering EGFR levels through promotion of EGFR ubiquitination and degradation and using Src kinase-mediated cell signaling to bypass their dependency on EGFR for cell growth and survival. [Cancer Res 2007;67(17):8240–7]

This article has been cited by other articles:

				J. Nevo, E. Mattila, T. Pellinen, D. L. Yamamoto, H. Sara, K. Iljin, O. Kallioniemi, P. Bono, P. Heikkila, H. Joensuu, et al. Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance Clin. Cancer Res., November 1, 2009; 15(21): 6570 - 6581. [Abstract] [Full Text] [PDF]

				D. L. Wheeler, M. Iida, and E. F. Dunn The Role of Src in Solid Tumors Oncologist, July 1, 2009; 14(7): 667 - 678. [Abstract] [Full Text] [PDF]

				S. Kopetz, D. P. Lesslie, N. A. Dallas, S. I. Park, M. Johnson, N. U. Parikh, M. P. Kim, J. L. Abbruzzese, L. M. Ellis, J. Chandra, et al. Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells Is Mediated by Oxidative Stress Cancer Res., May 1, 2009; 69(9): 3842 - 3849. [Abstract] [Full Text] [PDF]

				H. J.W.L. Aerts, L. Dubois, L. Perk, P. Vermaelen, G. A.M.S. van Dongen, B. G. Wouters, and P. Lambin Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET J. Nucl. Med., January 1, 2009; 50(1): 123 - 131. [Abstract] [Full Text] [PDF]

				F. Di Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. De Dosso, L. Mazzucchelli, M. Frattini, S. Siena, et al. Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer J. Clin. Oncol., December 10, 2008; 26(35): 5705 - 5712. [Abstract] [Full Text] [PDF]

				G. Lurje, F. Nagashima, W. Zhang, D. Yang, H. M. Chang, M. A. Gordon, A. El-Khoueiry, H. Husain, P. M. Wilson, R. D. Ladner, et al. Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab Clin. Cancer Res., December 1, 2008; 14(23): 7884 - 7895. [Abstract] [Full Text] [PDF]

				D. Wang, M. S. Veena, K. Stevenson, C. Tang, B. Ho, J. D. Suh, V. M. Duarte, K. F. Faull, K. Mehta, E. S. Srivatsan, et al. Liposome-Encapsulated Curcumin Suppresses Growth of Head and Neck Squamous Cell Carcinoma In vitro and in Xenografts through the Inhibition of Nuclear Factor {kappa}B by an AKT-Independent Pathway Clin. Cancer Res., October 1, 2008; 14(19): 6228 - 6236. [Abstract] [Full Text] [PDF]

				J. Wang, R. R. Seethala, Q. Zhang, W. Gooding, C. van Waes, H. Hasegawa, and R. L. Ferris Autocrine and Paracrine Chemokine Receptor 7 Activation in Head and Neck Cancer: Implications for Therapy J Natl Cancer Inst, April 2, 2008; 100(7): 502 - 512. [Abstract] [Full Text] [PDF]

				R. G. Amado, M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, D. J. Freeman, T. Juan, R. Sikorski, S. Suggs, R. Radinsky, et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer J. Clin. Oncol., April 1, 2008; 26(10): 1626 - 1634. [Abstract] [Full Text] [PDF]

				D. L. Shattuck, J. K. Miller, K. L. Carraway III, and C. Sweeney Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells Cancer Res., March 1, 2008; 68(5): 1471 - 1477. [Abstract] [Full Text] [PDF]